April 6, 2022 PEREGRINE VENTURES REALIZES USD 500 MILLION EXIT FROM CARTIHEAL FOLLOWING FDA APPROVAL OF IMPLANT FOR TREATMENT OF CARTILAGE AND OSTEOCHONDRAL DEFECTS USA – English USA – English
